Shire PLC (LON:SHP)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Credit Suisse Group in a report released on Monday. They presently have a GBX 4,500 ($59.38) price target on the biopharmaceutical company’s stock. Credit Suisse Group’s target price suggests a potential upside of 25.02% from the stock’s previous close.

A number of other analysts have also issued reports on SHP. Deutsche Bank AG restated a “buy” rating and issued a GBX 6,000 ($79.18) price target on shares of Shire PLC in a research note on Monday, July 3rd. Barclays PLC restated an “overweight” rating and issued a GBX 6,300 ($83.14) price target on shares of Shire PLC in a research note on Monday, July 3rd. HSBC Holdings plc upgraded shares of Shire PLC to a “hold” rating and set a GBX 4,450 ($58.72) price target for the company in a research note on Thursday, July 6th. Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a research note on Friday, July 7th. Finally, Liberum Capital restated a “hold” rating and issued a GBX 4,900 ($64.66) price target on shares of Shire PLC in a research note on Monday, July 10th. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of GBX 5,593.56 ($73.81).

Shire PLC (LON:SHP) opened at 3653.00 on Monday. The firm’s market cap is GBX 33.11 billion. Shire PLC has a one year low of GBX 3,435.50 and a one year high of GBX 5,186.00. The stock has a 50 day moving average of GBX 3,828.99 and a 200 day moving average of GBX 4,188.71.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/30/shire-plc-shp-stock-rating-reaffirmed-by-credit-suisse-group.html.

In other news, insider Anne Minto purchased 190 shares of Shire PLC stock in a transaction dated Friday, September 29th. The stock was bought at an average price of GBX 3,785 ($49.95) per share, with a total value of £7,191.50 ($9,489.97). Also, insider Flemming Ornskov purchased 8,400 shares of Shire PLC stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average cost of GBX 3,665 ($48.36) per share, with a total value of £307,860 ($406,254.95).

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.